.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Medtronic
McKinsey
Chinese Patent Office
Colorcon
Teva
Accenture
Baxter
Daiichi Sankyo
Julphar

Generated: November 18, 2017

DrugPatentWatch Database Preview

EOVIST Drug Profile

« Back to Dashboard

What is the patent landscape for Eovist, and when can generic versions of Eovist launch?

Eovist is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-three patent family members in twenty-four countries and five supplementary protection certificates in four countries.

The generic ingredient in EOVIST is gadoxetate disodium. One supplier is listed for this compound. Additional details are available on the gadoxetate disodium profile page.

Pharmacology for EOVIST

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare
EOVIST
gadoxetate disodium
SOLUTION;INTRAVENOUS022090-001Jul 3, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
Bayer Hlthcare
EOVIST
gadoxetate disodium
SOLUTION;INTRAVENOUS022090-001Jul 3, 2008RXYesYes► Subscribe► Subscribe► Subscribe
Bayer Hlthcare
EOVIST
gadoxetate disodium
SOLUTION;INTRAVENOUS022090-002Feb 4, 2013RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EOVIST

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Hlthcare
EOVIST
gadoxetate disodium
SOLUTION;INTRAVENOUS022090-001Jul 3, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: EOVIST

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,695,739 Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production► Subscribe
5,798,092 Derivatized DTPA complexes pharmaceutical agents containing these compounds, their use, and processes for their production► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: EOVIST

Country Document Number Estimated Expiration
German Democratic Republic296276► Subscribe
Australia637111► Subscribe
Czech Republic277926► Subscribe
Israel94818► Subscribe
Germany122004000051► Subscribe
New Zealand234295► Subscribe
Norway902925► Subscribe
Austria115546► Subscribe
HungaryT54622► Subscribe
Ireland65676► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: EOVIST

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB05/021United Kingdom► SubscribePRODUCT NAME: GADOXETIC ACID, OPTIONALLY IN THE FORM OF A SALT; REGISTERED: SE 18929 20040326; SE 18930 20040326; UK PL 00053/0348 20041110; UK PL 00053/0349 20041110
0405704/01Switzerland► SubscribeFORMER OWNER: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE
/2005Austria► SubscribePRODUCT NAME: GADOXETSAEURE DINATRIUM; NAT. REGISTRATION NO/DATE: 1-25757, 1-25758 20050302; FIRST REGISTRATION: SE 18929, 18930 20040326
00182Netherlands► SubscribePRODUCT: GADOXETINEZUUR, DESGEWENST IN DE VORM VAN EEN ZOUT, IN HET BIJZONDER HET NATRIUMZOUT. FIRST AUTHORIZATION NO/DATE: 1829 AND 18930, 20040326 (SE); NATIONAL AUTHORIZATION NO/DATE: RVG 31393 AND 31394, 20050113
0182Netherlands► Subscribe300182, 20100627, EXPIRES: 20150626
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
McKesson
Citi
QuintilesIMS
AstraZeneca
Accenture
US Department of Justice
Mallinckrodt
US Army
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot